Globus Medical AI Stock Analysis
Want to see GMED full AI Analyst Report?
Globus Medical (GMED) AI Stock Analysis
Globus Medical
(NYSE:GMED)
GMED’s score is primarily supported by strong financial quality—minimal leverage and robust, improving cash flow—alongside healthy profitability. The main offsets are weak technicals (trading below major moving averages with low RSI) and a mixed earnings update, where revenue guidance was cut and near-term top-line pressure persists despite maintained EPS and margin improvement.
Globus Medical Key Performance Indicators (KPIs)
Revenue By SegmentAnalyzes revenue from different business segments, highlighting which areas are driving growth and which may need strategic adjustments to improve performance.
Muscoloskeletal Solutions became the engine for growth after a clear inflection in late‑2023 and has sustained dramatically higher quarterly revenue into 2025, concentrating sales exposure in the core business and creating material operating‑leverage upside if volumes hold. Enabling Technologies is growing but remains volatile and much smaller—Q4 2025 spike hints at product or commercial cadence rather than steady revenue. Neuromonitoring is immaterial except a one‑quarter blip, underscoring limited diversification.
Globus Medical (GMED) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $9.34B
- Dividend Yield
- ―
- Average Volume (3M)
- 1.61M
- Price to Earnings (P/E)
- 17.0
- Beta (1Y)
- 0.72
- Revenue Growth
- 13.35%
- EPS Growth
- 32.22%
- Country
- US
- Employees
- 6,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Globus Medical Business Overview & Revenue Model
Company Description
Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extens...
How the Company Makes Money
Globus Medical generates revenue primarily by selling medical devices used in surgical procedures, with its core business historically centered on spine implants and the instruments and ancillary products required to implant them. Key revenue streams...
Globus Medical Earnings Call Summary
The call was broadly constructive, supported by record free cash flow, expanding margins, strong Trauma and Enabling Technologies growth, continued product launches and maintained EPS guidance. However, near-term performance is being constrained by the 25.7% Nevro revenue decline, delayed Spine launches, weaker competitive recruiting, international softness and a reduction in 2026 revenue guidance. Management remained confident in the longer-term trajectory, particularly for 2027.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For full year 2026, Globus Medical adjusted revenue guidance downward to $3.09 billion, compared to previous guidance of $3.18 billion to $3.22 billion, implying growth over 2025 of 5.1%; non-GAAP fully diluted earnings per share guidance remains in the range of $4.95 to $5.05, implying growth over 2025 ranging from 24.4% to 26.9%. The company reiterated adjusted gross profit margin in the range of 69% to 70% in 2026, representing a 90 to 190 basis point improvement over 2025, and expects R&D expense to be in the range of 4.5% to 5% of net sales for this year. Q4 guidance implies a mid-single-digit decline, while the company is not guiding on '27, though it said mid- to high single digits is where it would like to be for revenue growth, with earnings outperforming top line growth; it is also not guiding to free cash flow.
Globus Medical Financial Statement Overview
Summary
Financials are a net positive, led by a very strong balance sheet (very low leverage; debt-to-equity ~0.02) and robust, improving cash generation (TTM operating cash flow ~$926M; free cash flow ~$757M; free cash flow growth ~+79%). Profitability is healthy (TTM gross ~53%, EBIT ~16.6%, net ~17.8%), but the main risk is the recent TTM revenue decline (~-16.9%) and margin compression versus earlier years, which lowers growth confidence.
Income Statement
71PositiveBalance Sheet
88Very PositiveCash Flow
86Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.14B | 2.94B | 2.52B | 1.57B | 1.02B | 958.10M |
| Gross Profit | 2.20B | 1.98B | 1.48B | 1.02B | 759.12M | 718.88M |
| EBITDA | 984.28M | 886.74M | 473.73M | 346.58M | 304.50M | 264.73M |
| Net Income | 557.67M | 537.90M | 102.98M | 122.87M | 190.17M | 149.19M |
Balance Sheet | ||||||
| Total Assets | 5.53B | 5.30B | 5.25B | 5.09B | 2.08B | 1.96B |
| Cash, Cash Equivalents and Short-Term Investments | 517.43M | 557.24M | 890.06M | 517.79M | 446.06M | 443.45M |
| Total Debt | 107.55M | 118.66M | 537.19M | 520.40M | 6.01M | 0 |
| Total Liabilities | 731.94M | 729.51M | 1.07B | 1.09B | 229.75M | 215.88M |
| Stockholders Equity | 4.80B | 4.57B | 4.18B | 4.00B | 1.85B | 1.74B |
Cash Flow | ||||||
| Free Cash Flow | 756.55M | 588.77M | 405.21M | 165.22M | 104.42M | 219.38M |
| Operating Cash Flow | 925.92M | 753.45M | 520.64M | 243.50M | 178.47M | 276.27M |
| Investing Cash Flow | -579.07M | -355.01M | -176.05M | 302.97M | -110.36M | -375.94M |
| Financing Cash Flow | -233.84M | -679.16M | -27.70M | -231.82M | -109.96M | 54.15M |
Globus Medical Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GMED, the sentiment is Negative. The current price of 70.50 is below the 20-day moving average (MA) of 78.31, below the 50-day MA of 76.40, and below the 200-day MA of 82.60, indicating a bearish trend. The MACD of -1.40 indicates Positive momentum. The RSI at 39.58 is Neutral, neither overbought nor oversold. The STOCH value of 7.54 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GMED.
Globus Medical Risk Analysis
Globus Medical disclosed 56 risk factors in its most recent earnings report. Globus Medical reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksGlobus Medical Peers Comparison
Overall Rating
SYK75Outperform
GMED72Outperform
SIBN70Outperform
ZBH69Neutral
ATEC50Neutral
OFIX44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 75Outperform | $118.29B | 32.74 | 15.61% | 1.13% | 7.87% | 22.82% | |
| 72Outperform | $9.34B | 17.03 | 11.82% | ― | 13.35% | 32.22% | |
| 70Outperform | $1.06B | -75.31 | -7.57% | ― | 13.99% | 39.54% | |
| 69Neutral | $19.19B | 25.65 | 6.05% | 0.95% | 6.98% | -2.22% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $1.05B | -12.11 | -547.17% | ― | 15.34% | 46.31% | |
| 44Neutral | $277.17M | -6.14 | -10.32% | ― | 2.12% | 63.59% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GMED | Globus Medical | 70.50 | -13.32 | -15.89% | |
| ATEC | Alphatec | 6.78 | -12.84 | -65.44% | |
| OFIX | Orthofix Medical Inc. | 6.80 | -7.66 | -52.97% | |
| SYK | Stryker Corp | 310.72 | -49.52 | -13.75% | |
| ZBH | Zimmer Biomet Holdings | 101.41 | 12.91 | 14.58% | |
| SIBN | Si-Bone | 23.41 | 4.81 | 25.86% |
Globus Medical Corporate Events
Globus Medical Reports Third-Quarter 2026 Earnings Growth
PositiveOn November 5, 2026, Globus Medical reported third-quarter 2026 worldwide net sales of $763.7 million, down 0.7% year over year, while base-business sales excluding Nevro rose 3.0%. GAAP net income rose 18.7% to $141.2 million, diluted EPS increased...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026
